Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis

Abstract Heart failure (HF) and cardiovascular diseases present public health challenges. Although great progress was achieved in their treatment, there is continuous need for new therapies. Urocortins of the corticotropin neuropeptide family were reported to exert beneficial effects in animal model...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dóra K. Kovács, Nelli Farkas, Alexandra Soós, Péter Hegyi, Leonardo Kelava, Szimonetta Eitmann, Anna Schekk, Zsolt Molnár, Bálint Erőss, Márta Balaskó
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/141ce98328b344d28f6d9a2d310ae716
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:141ce98328b344d28f6d9a2d310ae716
record_format	dspace
spelling	oai:doaj.org-article:141ce98328b344d28f6d9a2d310ae7162021-11-19T17:51:35ZAssessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis1752-80621752-805410.1111/cts.13114https://doaj.org/article/141ce98328b344d28f6d9a2d310ae7162021-11-01T00:00:00Zhttps://doi.org/10.1111/cts.13114https://doaj.org/toc/1752-8054https://doaj.org/toc/1752-8062Abstract Heart failure (HF) and cardiovascular diseases present public health challenges. Although great progress was achieved in their treatment, there is continuous need for new therapies. Urocortins of the corticotropin neuropeptide family were reported to exert beneficial effects in animal models of HF and cardiovascular diseases. We aimed to assess the available clinical evidence on the potential role of urocortins in HF and other cardiovascular diseases. We explored MEDLINE, Embase, CENTRAL, and Scopus databases. Twenty‐seven studies were included in the qualitative and 15 studies (2005 patients) in the quantitative syntheses. Available data allowed us to meta‐analyze the blood pressure (BP) lowering and heart rate (HR) increasing effects of urocortin 2 in HF with reduced ejection fraction. We applied meta‐regression to explore the association between left ventricular ejection fraction and serum urocortin 1 and urocortin 2 levels. Short‐term urocortin 2 infusion decreased mean arterial pressure in chronic HF with reduced ejection fraction (mean difference = −9.161 mmHg, 95% confidence interval [CI] −12.661 to −5.660 mmHg, p < 0.001). Such infusions increased HR mildly (mean difference = 5.629 beats/min, 95% CI 1.612 to 9.646 beats/min, p = 0.006). Although some studies reported increased urocortin 1 and urocortin 2 levels in HF with growing severity, our meta‐regressions failed to confirm associations between blood urocortin levels and left ventricular ejection fraction. Clinical evidence confirms short‐term BP lowering effects of urocortin 2, whereas individual studies report additional beneficial effects. Further clinical investigations are necessary to confirm the latter and the long‐term value of these peptides in cardiovascular diseases. Review protocol: CRD42020163203.Dóra K. KovácsNelli FarkasAlexandra SoósPéter HegyiLeonardo KelavaSzimonetta EitmannAnna SchekkZsolt MolnárBálint ErőssMárta BalaskóWileyarticleTherapeutics. PharmacologyRM1-950Public aspects of medicineRA1-1270ENClinical and Translational Science, Vol 14, Iss 6, Pp 2461-2473 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
spellingShingle	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270 Dóra K. Kovács Nelli Farkas Alexandra Soós Péter Hegyi Leonardo Kelava Szimonetta Eitmann Anna Schekk Zsolt Molnár Bálint Erőss Márta Balaskó Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis
description	Abstract Heart failure (HF) and cardiovascular diseases present public health challenges. Although great progress was achieved in their treatment, there is continuous need for new therapies. Urocortins of the corticotropin neuropeptide family were reported to exert beneficial effects in animal models of HF and cardiovascular diseases. We aimed to assess the available clinical evidence on the potential role of urocortins in HF and other cardiovascular diseases. We explored MEDLINE, Embase, CENTRAL, and Scopus databases. Twenty‐seven studies were included in the qualitative and 15 studies (2005 patients) in the quantitative syntheses. Available data allowed us to meta‐analyze the blood pressure (BP) lowering and heart rate (HR) increasing effects of urocortin 2 in HF with reduced ejection fraction. We applied meta‐regression to explore the association between left ventricular ejection fraction and serum urocortin 1 and urocortin 2 levels. Short‐term urocortin 2 infusion decreased mean arterial pressure in chronic HF with reduced ejection fraction (mean difference = −9.161 mmHg, 95% confidence interval [CI] −12.661 to −5.660 mmHg, p < 0.001). Such infusions increased HR mildly (mean difference = 5.629 beats/min, 95% CI 1.612 to 9.646 beats/min, p = 0.006). Although some studies reported increased urocortin 1 and urocortin 2 levels in HF with growing severity, our meta‐regressions failed to confirm associations between blood urocortin levels and left ventricular ejection fraction. Clinical evidence confirms short‐term BP lowering effects of urocortin 2, whereas individual studies report additional beneficial effects. Further clinical investigations are necessary to confirm the latter and the long‐term value of these peptides in cardiovascular diseases. Review protocol: CRD42020163203.
format	article
author	Dóra K. Kovács Nelli Farkas Alexandra Soós Péter Hegyi Leonardo Kelava Szimonetta Eitmann Anna Schekk Zsolt Molnár Bálint Erőss Márta Balaskó
author_facet	Dóra K. Kovács Nelli Farkas Alexandra Soós Péter Hegyi Leonardo Kelava Szimonetta Eitmann Anna Schekk Zsolt Molnár Bálint Erőss Márta Balaskó
author_sort	Dóra K. Kovács
title	Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis
title_short	Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis
title_full	Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis
title_fullStr	Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis
title_full_unstemmed	Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis
title_sort	assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: a systematic review and meta‐analysis
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/141ce98328b344d28f6d9a2d310ae716
work_keys_str_mv	AT dorakkovacs assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT nellifarkas assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT alexandrasoos assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT peterhegyi assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT leonardokelava assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT szimonettaeitmann assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT annaschekk assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT zsoltmolnar assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT balinteross assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis AT martabalasko assessmentofclinicaldataonurocortinsandtheirtherapeuticpotentialincardiovasculardiseasesasystematicreviewandmetaanalysis
_version_	1718419996360572928

Assessment of clinical data on urocortins and their therapeutic potential in cardiovascular diseases: A systematic review and meta‐analysis

Ejemplares similares